131 related articles for article (PubMed ID: 30651632)
1. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
Alfonso V; Iaccarino L; Ottone T; Cicconi L; Lavorgna S; Divona M; Cairoli R; Cristiano A; Ciardi C; Travaglini S; Falconi G; Hasan SK; Venditti A; Arcese W; Voso MT; Lo-Coco F
Leukemia; 2019 Jun; 33(6):1527-1530. PubMed ID: 30651632
[No Abstract] [Full Text] [Related]
2. Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.
Dubey S; Mishra N; Shelke R; Varma AK
FEBS J; 2024 Apr; 291(7):1422-1438. PubMed ID: 38129745
[TBL] [Abstract][Full Text] [Related]
3. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
4. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
5. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
6. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
Iaccarino L; Ottone T; Alfonso V; Cicconi L; Divona M; Lavorgna S; Travaglini S; Ferrantini A; Falconi G; Baer C; Usai M; Forghieri F; Venditti A; Del Principe MI; Arcese W; Voso MT; Haferlach T; Lo-Coco F
Am J Hematol; 2019 Oct; 94(10):1091-1097. PubMed ID: 31292998
[TBL] [Abstract][Full Text] [Related]
7. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
8. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
[TBL] [Abstract][Full Text] [Related]
9. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
Lehmann-Che J; Bally C; Letouzé E; Berthier C; Yuan H; Jollivet F; Ades L; Cassinat B; Hirsch P; Pigneux A; Mozziconacci MJ; Kogan S; Fenaux P; de Thé H
Nat Commun; 2018 May; 9(1):2047. PubMed ID: 29795382
[TBL] [Abstract][Full Text] [Related]
10. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
11. Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Iaccarino L; Ottone T; Hasan SK; Divona M; Cicconi L; Lavorgna S; Alfonso V; Basso G; Barragán E; Bocchia M; Rego EM; Grimwade D; Voso MT; Lo-Coco F
Leuk Lymphoma; 2018 May; 59(5):1268-1270. PubMed ID: 28838264
[No Abstract] [Full Text] [Related]
12. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
[TBL] [Abstract][Full Text] [Related]
13. Identification of a point mutation PML
Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
[TBL] [Abstract][Full Text] [Related]
14. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
Ha JS; Do YR; Ki CS; Lee C; Kim DH; Lee W; Ryoo NH; Jeon DS
Leukemia; 2017 Sep; 31(9):1992-1995. PubMed ID: 28555082
[No Abstract] [Full Text] [Related]
16. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Dagher T; Maslah N; Edmond V; Cassinat B; Vainchenker W; Giraudier S; Pasquier F; Verger E; Niwa-Kawakita M; Lallemand-Breitenbach V; Plo I; Kiladjian JJ; Villeval JL; de Thé H
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33075130
[TBL] [Abstract][Full Text] [Related]
17. Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.
Jiang YH; Chen YJ; Wang C; Lan YF; Yang C; Wang QQ; Hussain L; Maimaitiying Y; Islam K; Naranmandura H
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28125064
[TBL] [Abstract][Full Text] [Related]
18. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
[TBL] [Abstract][Full Text] [Related]
19. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Mathews V; Thomas M; Srivastava VM; George B; Srivastava A; Chandy M
Haematologica; 2007 Jul; 92(7):994-5. PubMed ID: 17606455
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
